Public willingness to participate in population DNA screening in Australia.

Autor:	Tiller JM; School of Public Health and Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia jane.tiller@monash.edu., Bakshi A; School of Public Health and Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia., Brotchie AR; School of Public Health and Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia., Green RC; Harvard Medical School, Boston, Massachusetts, USA., Winship IM; Clinical Genetics, Royal Melbourne Hospital, Parkville, Victoria, Australia., Lacaze P; School of Public Health and Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Victoria, Australia.
Jazyk:	angličtina
Zdroj:	Journal of medical genetics [J Med Genet] 2023 Jul; Vol. 60 (7), pp. 662-668. Date of Electronic Publication: 2022 Nov 30.
DOI:	10.1136/jmg-2022-108921
Abstrakt:	Background: Population-based DNA screening for medically actionable conditions has the potential to improve public health by enabling early detection, treatment and/or prevention; however, public attitudes and willingness to participate in DNA screening have not been well investigated. Methods: We presented a scenario to members of the Australian public, randomly selected from the electoral roll via the Australian Survey of Societal Attitudes, describing an adult population DNA screening programme currently under development, to detect risk of medically actionable cancers and heart disease. We asked questions regarding willingness to participate and pay, preferred delivery methods and concerns. Results: We received 1060 completed questionnaires (response rate 23%, mean age 58 years). The vast majority (>92%) expressed willingness to undertake DNA screening. When asked about the optimal age of screening, most (56%) favoured early adulthood (aged 18-40 years) rather than at birth or childhood. Many respondents would prefer samples and data be kept for re-screening (36%) or research use (43%); some preferred samples to be destroyed (21%). Issues that decrease likelihood of participation included privacy (75%) and insurance (86%) implications. Conclusion: Our study demonstrates public willingness to participate in population DNA screening in Australia, and identifies barriers to participation, to be addressed in the design of screening programmes. Results are informing the development of a pilot national DNA screening programme. Competing Interests: Competing interests: RG has received compensation for advising the following companies: AIA, Allelica, Fabric, Genome Web, Genomic Life, Grail, Humanity, OptumLabs, Verily, VinBigData; and is co-founder of Genome Medical and Nurture Genomics. PL, JMT, IW and AB are named investigators on and ARB is project manager of the DNA Screen study, which is funded by an Australian Government Medical Research Futures Fund Genomics Health Futures Mission grant no. 2021/MRF2009024. (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu